- Home
- PRVA vs TARS Comparison
PRVA vs TARS Comparison
Compare PRVA & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRVA
- TARS
- Stock Information
- Founded
- PRVA 2007
- TARS 2016
- Country
- PRVA United States
- TARS United States
- Employees
- PRVA N/A
- TARS N/A
- Industry
- PRVA Retail: Computer Software & Peripheral Equipment
- TARS Medicinal Chemicals and Botanical Products
- Sector
- PRVA Technology
- TARS Health Care
- Exchange
- PRVA Nasdaq
- TARS Nasdaq
- Market Cap
- PRVA 3.1B
- TARS 2.8B
- IPO Year
- PRVA 2021
- TARS 2020
- Fundamental
- Price
- PRVA $24.78
- TARS $69.79
- Analyst Decision
- PRVA Strong Buy
- TARS Strong Buy
- Analyst Count
- PRVA 13
- TARS 7
- Target Price
- PRVA $29.08
- TARS $69.43
- AVG Volume (30 Days)
- PRVA 722.9K
- TARS 513.3K
- Earning Date
- PRVA 11-06-2025
- TARS 11-04-2025
- Dividend Yield
- PRVA N/A
- TARS N/A
- EPS Growth
- PRVA N/A
- TARS N/A
- EPS
- PRVA 0.11
- TARS N/A
- Revenue
- PRVA $1,900,071,000.00
- TARS $295,521,000.00
- Revenue This Year
- PRVA $96.90
- TARS $139.46
- Revenue Next Year
- PRVA $1.02
- TARS $49.91
- P/E Ratio
- PRVA $225.32
- TARS N/A
- Revenue Growth
- PRVA 12.05
- TARS 254.45
- 52 Week Low
- PRVA $18.51
- TARS $38.51
- 52 Week High
- PRVA $26.49
- TARS $76.81
- Technical
- Relative Strength Index (RSI)
- PRVA 49.81
- TARS 59.16
- Support Level
- PRVA $25.67
- TARS $66.31
- Resistance Level
- PRVA $26.12
- TARS $70.84
- Average True Range (ATR)
- PRVA 0.66
- TARS 2.85
- MACD
- PRVA -0.22
- TARS -0.71
- Stochastic Oscillator
- PRVA 32.94
- TARS 39.01
About PRVA Privia Health Group Inc.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.